EmyriaASX:EMD -2.63% Days Payable is 93.10 as of Dec. 2025, which is 1% above its 10-year median of 91.83. The stock has 1 warning sign investors should review. Among 606 Healthcare Providers & Services companies, Emyria ranks better than 76.24% on this metric.
Emyria's average Accounts Payable for the
six
months ended in Dec. 2025 was A$0.61 Mil. Emyria's Cost of Goods Sold for the
six
months ended in Dec. 2025 was A$1.19 Mil.
Hence, Emyria's Days Payable for the
six
months ended in Dec. 2025 was 93.10.
The historical rank and industry rank for Emyria's Days Payable or its related term are showing as below:
ASX:EMD'
s Days Payable Range Over the Past 10 Years
Min: 31.83 Med: 91.83 Max: 199.45
Current: 128.85
During the past 7 years, Emyria's highest Days Payable was 199.45. The lowest was 31.83. And the median was 91.83.
ASX:EMD's Days Payable is ranked better than 76.24% of 606
companies
in the Healthcare Providers & Services industry
Industry Median: 58.205
vs ASX:EMD: 128.85
Emyria's Days Payable
declined
from Dec. 2024 (154.51) to Dec. 2025 (93.10).
It may suggest that Emyriaaccelerated paying its suppliers.
Emyria Days Payable Related Terms
Emyria Days Payable Historical Data
* Premium members only.
The historical data trend for Emyria's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EMD vs VEEV, BTSG, TEM: Days Payable Comparison
For the Health Information Services subindustry, Emyria's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emyria Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Emyria's Days Payable distribution charts can be found below:
* The bar in red indicates where Emyria's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Emyria's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emyria (ASX:EMD) has a Days Payable of 93.10 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Emyria and its competitors. This is near median its historical median of 91.83. Over the past decade, Emyria's Days Payable has ranged from 31.83 to 199.45. According to the industry distribution chart, Emyria ranks #144 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 23.8%.
Is Emyria's Days Payable too high?
Emyria's current Days Payable of 93.10 is near median its 10-year median of 91.83. Over the past 10 years, this metric has ranged from a low of 31.83 to a high of 199.45. The Healthcare Providers & Services industry median Days Payable is 58.21. Emyria's value of 93.10 is 60% above this industry median. Based on the distribution chart, Emyria ranks #144 out of 606 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Emyria's Days Payable compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Emyria ranks #144 out of 606 companies for Days Payable. This places Emyria in the top 24% of its industry — outperforming the majority of peers. The industry median Days Payable is 58.21. Emyria's value of 93.10 is 60% above this benchmark. Historically, Emyria's own Days Payable has ranged from 31.83 to 199.45 over the past decade. While the company's 10-year median is 91.83 vs. the industry median of 58.21, Emyria has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.21, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emyria's current Days Payable of 93.10 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Emyria and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emyria's current Days Payable is 93.10, which is near median its own 10-year median of 91.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emyria stock overvalued right now?
Based on GuruFocus' analysis, Emyria (ASX:EMD) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.04 — trading 23.3% above its estimated fair value. The current Days Payable is 93.10, which is near median its 10-year median of 91.83 and 60% above the Healthcare Providers & Services industry median of 58.21. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Emyria (ASX:EMD), the current Days Payable is 93.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emyria Ltd operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. It operates in one segment of research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EMD has been successfully added to your 